"One of Wall Streets Top Players" says, The New York Times ………………………………………….. a " Financial Prodigy " says, Forbes Magazine…………………………………………….. The " Zelig Of WallStreet" calls the LA. Times

  • Nike 3.0 womens
  • Nike free 5.0 kids
  • Oakley Radar Sunglass
  • jordan 11 gamma
  • Womens Air Jordan 11
  • Latest

    Catasys Commences Enrollment for Its OnTrak™ Program in New Jersey with Leading Health Insurance Provider

    Company Expands Coverage by more than 500,000 Commercial Equivalent Lives

    Los Angeles, California — February 26, 2015 /PRNewswire/—Catasys, Inc. (CATS) provider of proprietary health management services to health insurers and other third party payors, is pleased to announce that it has expanded its Catasys’ OnTrak™ program into New Jersey with one of the nation’s leading national health plans. The plan’s eligible commercial health plan members will be covered under the OnTrak program, which includes medical and psychosocial interventions, as well as intensive care coaching over 52-weeks. Terren Peizer, Founder, Chairman and CEO, and 67% owner of Catasys, Inc. through his personal investment vehicle Crede Capital Group, commented, “We now have two leading national health plans, Humana and Aetna, and Medicaid leader, Centene, Inc. , and Fallon Healthcare now operating in 9 states. We anticipate rapid expansion amongst health plans throughout the industry as well as geographical expansion within the health plans over the coming year. We also anticipate rolling out similar programs for other behavioral health disease conditions, such as anxiety and depression. We proudly are improving patient health, providing significant cost savings to the healthcare system, and incentivising health plans to pay for the necessary treatment costs that patients require. Catasys’ OnTrak program is a game-changer.”

    “Given the success of our enrollments, we are excited to expand into New Jersey with one of the largest health plans in the nation serving more than 20 million medical members. We look forward to working with patients in New Jersey to provide medical and behavioral treatment in a patient-centric, long-term program that provides individualized support and coaching to members addressed by our OnTrak program. Our outcomes demonstrate that overall, members who have enrolled in the OnTrak program have achieved improved health and reduced hospital admissions,” said Rick Anderson, Catasys’ President and COO. “Our initial focus is on improving the whole health of people with substance use disorders in order to reduce health care costs for insurers and other payors. This is a multi-billion dollar opportunity, and through our business model, we have already demonstrated greater than 50% reduction in health plan healthcare costs for members enrolled in our program. We look forward to delivering similar results in this plan and continue to focus on further expanding this program nationally; as we are with many of our other national plans.”

    Catasys has contracts with many health insurance providers and currently has approximately 1.8 million Commercially Equivalent Lives (CELs) covered under contracts and located in nine states, which is anticipated to allow the Company to achieve profitability once full steady state enrollment is achieved. For more information and a list of Catasys’ customers, please refer to the corporate presentation posted on the Investors section of the Company’swebsite.

    About Catasys
    Catasys, Inc. provides specialized healthcare management services to health plans and employers through its OnTrak program. Catasys’ OnTrakprogram – contracted with a growing number of health insurers – is designed to improve member health and at the same time lower costs to the insurer for underserved populations where behavioral health conditions are exacerbating co-existing medical conditions. The program utilizes member engagement and patient centric treatment that integrates evidence based medical and psychosocial interventions along with care coaching in a 52-week outpatient program. OnTrak is currently improving member health and, at the same time, is demonstrating reduced inpatient and emergency room utilization driving a more than 50% reduction in total health insurers’ costs for enrolled members. Catasys has contracts with many health insurance providers and currently has approximately 1.8 million Commercially Equivalent Lives (CELs) covered under contracts and located in nine states. Catasys’ initial focus is on the high cost substance abuse populations, where it has incentivized health plans to spend more on behavioral health to improve overall member health resulting in lower hospital utilization and cost. In addition, Catasys is looking towards other populations and behavioral health disease conditions to expand to in the future. For further information, please visitwww.catasys.com.

    Forward-Looking Statements
    Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, changes in regulations or issuance of new regulations or interpretations, limited operating history, our inability to execute our business plan, increase our revenue and achieve profitability, lower than anticipated eligible members under our contracts, our inability to recognize revenue, lack of outcomes and statistically significant formal research studies, difficulty enrolling new and maintain existing members in our programs, the risk that treatment programs might not be effective, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the health care industry, the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern, our ability to raise additional capital when needed and our liquidity. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plan,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties we face, please refer to our most recent Securities and Exchange Commission filings which are available on its website at http://www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    Catasys Commences Enrollment for Its OnTrak™ Program in New Jersey with Leading Health Insurance Provider

    Company Expands Coverage by more than 500,000 Commercial Equivalent Lives

    Los Angeles, California — February 26, 2015 /PRNewswire/—Catasys, Inc. (CATS) provider of proprietary health management services to health insurers and other third party payors, is pleased to announce that it has expanded its Catasys’ OnTrak™ program into New Jersey with one of the nation’s leading national health plans. The plan’s eligible commercial health plan members will be covered under the OnTrak program, which includes medical and psychosocial interventions, as well as intensive care coaching over 52-weeks. Terren Peizer, Founder, Chairman and CEO, and 67% owner of Catasys, Inc. through his personal investment vehicle Crede Capital Group, commented, “We now have two leading national health plans, Humana and Aetna, and Medicaid leader, Centene, Inc. , and Fallon Healthcare now operating in 9 states. We anticipate rapid expansion amongst health plans throughout the industry as well as geographical expansion within the health plans over the coming year. We also anticipate rolling out similar programs for other behavioral health disease conditions, such as anxiety and depression. We proudly are improving patient health, providing significant cost savings to the healthcare system, and incentivising health plans to pay for the necessary treatment costs that patients require. Catasys’ OnTrak program is a game-changer.”

    “Given the success of our enrollments, we are excited to expand into New Jersey with one of the largest health plans in the nation serving more than 20 million medical members. We look forward to working with patients in New Jersey to provide medical and behavioral treatment in a patient-centric, long-term program that provides individualized support and coaching to members addressed by our OnTrak program. Our outcomes demonstrate that overall, members who have enrolled in the OnTrak program have achieved improved health and reduced hospital admissions,” said Rick Anderson, Catasys’ President and COO. “Our initial focus is on improving the whole health of people with substance use disorders in order to reduce health care costs for insurers and other payors. This is a multi-billion dollar opportunity, and through our business model, we have already demonstrated greater than 50% reduction in health plan healthcare costs for members enrolled in our program. We look forward to delivering similar results in this plan and continue to focus on further expanding this program nationally; as we are with many of our other national plans.”

    Catasys has contracts with many health insurance providers and currently has approximately 1.8 million Commercially Equivalent Lives (CELs) covered under contracts and located in nine states, which is anticipated to allow the Company to achieve profitability once full steady state enrollment is achieved. For more information and a list of Catasys’ customers, please refer to the corporate presentation posted on the Investors section of the Company’swebsite.

    About Catasys
    Catasys, Inc. provides specialized healthcare management services to health plans and employers through its OnTrak program. Catasys’ OnTrakprogram – contracted with a growing number of health insurers – is designed to improve member health and at the same time lower costs to the insurer for underserved populations where behavioral health conditions are exacerbating co-existing medical conditions. The program utilizes member engagement and patient centric treatment that integrates evidence based medical and psychosocial interventions along with care coaching in a 52-week outpatient program. OnTrak is currently improving member health and, at the same time, is demonstrating reduced inpatient and emergency room utilization driving a more than 50% reduction in total health insurers’ costs for enrolled members. Catasys has contracts with many health insurance providers and currently has approximately 1.8 million Commercially Equivalent Lives (CELs) covered under contracts and located in nine states. Catasys’ initial focus is on the high cost substance abuse populations, where it has incentivized health plans to spend more on behavioral health to improve overall member health resulting in lower hospital utilization and cost. In addition, Catasys is looking towards other populations and behavioral health disease conditions to expand to in the future. For further information, please visitwww.catasys.com.

    Forward-Looking Statements
    Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, changes in regulations or issuance of new regulations or interpretations, limited operating history, our inability to execute our business plan, increase our revenue and achieve profitability, lower than anticipated eligible members under our contracts, our inability to recognize revenue, lack of outcomes and statistically significant formal research studies, difficulty enrolling new and maintain existing members in our programs, the risk that treatment programs might not be effective, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the health care industry, the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern, our ability to raise additional capital when needed and our liquidity. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plan,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties we face, please refer to our most recent Securities and Exchange Commission filings which are available on its website at http://www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    Catasys Commences Enrollment for Its OnTrak™ Program in New Jersey with Leading Health Insurance Provider

    Company Expands Coverage by more than 500,000 Commercial Equivalent Lives

    Los Angeles, California — February 26, 2015 /PRNewswire/—Catasys, Inc. (CATS) provider of proprietary health management services to health insurers and other third party payors, is pleased to announce that it has expanded its Catasys’ OnTrak™ program into New Jersey with one of the nation’s leading national health plans. The plan’s eligible commercial health plan members will be covered under the OnTrak program, which includes medical and psychosocial interventions, as well as intensive care coaching over 52-weeks. Terren Peizer, Founder, Chairman and CEO, and 67% owner of Catasys, Inc. through his personal investment vehicle Crede Capital Group, commented, “We now have two leading national health plans, Humana and Aetna, and Medicaid leader, Centene, Inc. , and Fallon Healthcare now operating in 9 states. We anticipate rapid expansion amongst health plans throughout the industry as well as geographical expansion within the health plans over the coming year. We also anticipate rolling out similar programs for other behavioral health disease conditions, such as anxiety and depression. We proudly are improving patient health, providing significant cost savings to the healthcare system, and incentivising health plans to pay for the necessary treatment costs that patients require. Catasys’ OnTrak program is a game-changer.”

    “Given the success of our enrollments, we are excited to expand into New Jersey with one of the largest health plans in the nation serving more than 20 million medical members. We look forward to working with patients in New Jersey to provide medical and behavioral treatment in a patient-centric, long-term program that provides individualized support and coaching to members addressed by our OnTrak program. Our outcomes demonstrate that overall, members who have enrolled in the OnTrak program have achieved improved health and reduced hospital admissions,” said Rick Anderson, Catasys’ President and COO. “Our initial focus is on improving the whole health of people with substance use disorders in order to reduce health care costs for insurers and other payors. This is a multi-billion dollar opportunity, and through our business model, we have already demonstrated greater than 50% reduction in health plan healthcare costs for members enrolled in our program. We look forward to delivering similar results in this plan and continue to focus on further expanding this program nationally; as we are with many of our other national plans.”

    Catasys has contracts with many health insurance providers and currently has approximately 1.8 million Commercially Equivalent Lives (CELs) covered under contracts and located in nine states, which is anticipated to allow the Company to achieve profitability once full steady state enrollment is achieved. For more information and a list of Catasys’ customers, please refer to the corporate presentation posted on the Investors section of the Company’swebsite.

    About Catasys
    Catasys, Inc. provides specialized healthcare management services to health plans and employers through its OnTrak program. Catasys’ OnTrakprogram – contracted with a growing number of health insurers – is designed to improve member health and at the same time lower costs to the insurer for underserved populations where behavioral health conditions are exacerbating co-existing medical conditions. The program utilizes member engagement and patient centric treatment that integrates evidence based medical and psychosocial interventions along with care coaching in a 52-week outpatient program. OnTrak is currently improving member health and, at the same time, is demonstrating reduced inpatient and emergency room utilization driving a more than 50% reduction in total health insurers’ costs for enrolled members. Catasys has contracts with many health insurance providers and currently has approximately 1.8 million Commercially Equivalent Lives (CELs) covered under contracts and located in nine states. Catasys’ initial focus is on the high cost substance abuse populations, where it has incentivized health plans to spend more on behavioral health to improve overall member health resulting in lower hospital utilization and cost. In addition, Catasys is looking towards other populations and behavioral health disease conditions to expand to in the future. For further information, please visitwww.catasys.com.

    Forward-Looking Statements
    Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, changes in regulations or issuance of new regulations or interpretations, limited operating history, our inability to execute our business plan, increase our revenue and achieve profitability, lower than anticipated eligible members under our contracts, our inability to recognize revenue, lack of outcomes and statistically significant formal research studies, difficulty enrolling new and maintain existing members in our programs, the risk that treatment programs might not be effective, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the health care industry, the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern, our ability to raise additional capital when needed and our liquidity. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plan,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties we face, please refer to our most recent Securities and Exchange Commission filings which are available on its website at http://www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    CREDE CAPITAL GROUP BUYS 10% OF FRENCH BIOTECH COMPANY, HYBRIGENICS; STOCK RISES 72%

    Paris, 28 October 2014 – Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments against proliferative diseases and specialised in proteomic and genomic scientific services, today announces the successful completion of a private placement for $6 million to the Crede Capital Group, llc, a US-based family office, which has completed numerous investments in European life sciences companies. Terren Peizer, Chairman of Crede Capital Group, his personal investment vehicle, commented, “We are gratified that the market is recognizing what we believe; that Hybigenics’ vitamin D receptor agonist  represents an important drug candidate for the treatment of castrate resistant prostate cancer. We are proud to provide the Company with the capital to commercialize this intriguing drug candidate.”

     

    A total of 3,500,000 new shares have been issued at €1.32 each, representing a 20% discount to the 5-day volume weighted average price of Hybrigenics shares prior to the operation which was completed on the basis of the delegation in place according to the 11th resolution voted by the Shareholders’ Meeting of June 20, 2014 with respect to private placements to qualified investors or to a small number of investors with the meaning of the paragraph II of article L. 411-2 of the French financial and monetary Code. The new shares are of the same class as existing shares and represent 13.5% of Hybrigenics’ capital before the capital raise and 11.9% after.

    The success of this capital increase by Crede Capital Group, a US family office, demonstrates the attractiveness of Hybrigenics. Hybrigenics combines the clinical development of inecalcitol in orphan adult leukemias, the research collaboration with Servier and the expanding business of proteomic and genomic services. This capital increase will enable Hybrigenics to strengthen its research and clinical development activities,” said Remi Delansorne, Hybrigenics’ CEO.

     

    About Hybrigenics

    Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical group listed (ALHYG) on the Alternext market of Euronext Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative diseases and providing cutting-edge proteomic and genomic scientific services.

    Hybrigenics’ current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication. Oral inecalcitol has also been tested in chronic lymphocytic leukemia patients, an indication for which inecalcitol has received orphan drug status in Europe and the United States.

    Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology.

    Hybrigenics Services (www.hybrigenics-services.com) is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform.

    Helixio (www.helixio.com), Hybrigenics’ genomic branch, provides state-of-the-art services specialized in DNA chips, DNA or RNA target enrichment and next generation sequencing with an Illumina NextSeq500.

    Hybrigenics Corp., based in Cambridge, Mass., is the American subsidiary of Hybrigenics.

    CREDE CAPITAL GROUP BUYS 10% OF FRENCH BIOTECH COMPANY, HYBRIGENICS; STOCK RISES 72%

    Paris, 28 October 2014 – Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments against proliferative diseases and specialised in proteomic and genomic scientific services, today announces the successful completion of a private placement for $6 million to the Crede Capital Group, llc, a US-based family office, which has completed numerous investments in European life sciences companies. Terren Peizer, Chairman of Crede Capital Group, his personal investment vehicle, commented, “We are gratified that the market is recognizing what we believe; that Hybigenics’ vitamin D receptor agonist  represents an important drug candidate for the treatment of castrate resistant prostate cancer. We are proud to provide the Company with the capital to commercialize this intriguing drug candidate.”

     

    A total of 3,500,000 new shares have been issued at €1.32 each, representing a 20% discount to the 5-day volume weighted average price of Hybrigenics shares prior to the operation which was completed on the basis of the delegation in place according to the 11th resolution voted by the Shareholders’ Meeting of June 20, 2014 with respect to private placements to qualified investors or to a small number of investors with the meaning of the paragraph II of article L. 411-2 of the French financial and monetary Code. The new shares are of the same class as existing shares and represent 13.5% of Hybrigenics’ capital before the capital raise and 11.9% after.

    The success of this capital increase by Crede Capital Group, a US family office, demonstrates the attractiveness of Hybrigenics. Hybrigenics combines the clinical development of inecalcitol in orphan adult leukemias, the research collaboration with Servier and the expanding business of proteomic and genomic services. This capital increase will enable Hybrigenics to strengthen its research and clinical development activities,” said Remi Delansorne, Hybrigenics’ CEO.

     

    About Hybrigenics

    Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical group listed (ALHYG) on the Alternext market of Euronext Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative diseases and providing cutting-edge proteomic and genomic scientific services.

    Hybrigenics’ current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication. Oral inecalcitol has also been tested in chronic lymphocytic leukemia patients, an indication for which inecalcitol has received orphan drug status in Europe and the United States.

    Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology.

    Hybrigenics Services (www.hybrigenics-services.com) is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform.

    Helixio (www.helixio.com), Hybrigenics’ genomic branch, provides state-of-the-art services specialized in DNA chips, DNA or RNA target enrichment and next generation sequencing with an Illumina NextSeq500.

    Hybrigenics Corp., based in Cambridge, Mass., is the American subsidiary of Hybrigenics.

    Crede Capital’s Catasys, Inc. market value soars to over $100 million on Seeking Alpha Report.

    Crede Capital Group’s 69% owned Catasys, Inc.’s market value soared to over $100 million on a Seeking Alpha Report. Terren Peizer, Chairman of Crede Capital, his personal investment vehicle, and Founder, Chairman, and CEO of Catasys, Inc., commented, “This coming year we should begin to demonstrate that we are in the process of significantly changing the Behavioral Health Industry; as the recent widely reported tragic deaths of Seymour Hoffman and Robin Williams point out the incredible need to do so. With every mass school killing; with every movie theater mass killing, the conversation has been gradually shifting from NRA issues to the broken Behavioral Healthcare System. We are certainly the pioneer and leader in this effort. We were the first to identify the problem , quantify the problem, provide a solution, and incentivise Health Insurance companies to pay for 100% of the treatment costs that patients need to improve both behavioral and physical medical health. Heretofore, healthcare insurance companies covered minimal behavioral health claims and costs, unlike the coverage for other diseases like oncological and cardiovascular diseases. Over the next three years, we expect to cover over 100 million lives and emerge as the defacto standard for Behavioral Health treatment and care. ”

    Catasys’ Unique Delivery Of Cost Savings To Insurers Could Drive Significant Upside Within 12 Months
    Catasys (OTCQB:CATS) is an emerging growth…
    SEEKINGALPHA.COM